首页> 美国卫生研究院文献>Cancers >The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer
【2h】

The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer

机译:组蛋白脱甲基酶KDM3A和KDM4B协同调节乳腺癌中雌激素受体的染色质交易。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Many estrogen receptor (ER)-positive breast cancers develop resistance to endocrine therapy but retain canonical receptor signalling in the presence of selective ER antagonists. Numerous co-regulatory proteins, including enzymes that modulate the chromatin environment, control the transcriptional activity of the ER. Targeting ER co-regulators has therefore been proposed as a novel therapeutic approach. By assessing DNA-binding dynamics in ER-positive breast cancer cells, we have identified that the histone H3 lysine 9 demethylase enzymes, KDM3A and KDM4B, co-operate to regulate ER activity via an auto-regulatory loop that facilitates the recruitment of each co-activating enzyme to chromatin. We also provide evidence that suggests that KDM3A primes chromatin for deposition of the ER pioneer factor FOXA1 and recruitment of the ER-transcriptional complex, all prior to ER recruitment, therefore establishing an important mechanism of chromatin regulation involving histone demethylases and pioneer factors, which controls ER functionality. Importantly, we show via global gene-expression analysis that a KDM3A/KDM4B/FOXA1 co-regulated gene signature is enriched for pro-proliferative and ER-target gene sets, suggesting that abrogation of this network could be an efficacious therapeutic strategy. Finally, we show that depletion of both KDM3A and KDM4B has a greater inhibitory effect on ER activity and cell growth than knockdown of each individual enzyme, suggesting that targeting both enzymes represents a potentially efficacious therapeutic option for ER-driven breast cancer.
机译:许多雌激素受体(ER)阳性乳腺癌对内分泌治疗产生抗药性,但在存在选择性ER拮抗剂的情况下仍保留规范的受体信号传导。许多共调节蛋白,包括调节染色质环境的酶,都控制着ER的转录活性。因此已经提出了靶向ER共调节剂作为一种新颖的治疗方法。通过评估ER阳性乳腺癌细胞中的DNA结合动力学,我们已经确定,组蛋白H3赖氨酸9脱甲基酶KDM3A和KDM4B通过自动调节回路协同调节ER活性,从而促进了每个公司的募集活化酶染色质。我们还提供证据表明,在ER募集之前,KDM3A会引发染色质沉积ER先锋因子FOXA1和招募ER转录复合体,因此建立了涉及组蛋白脱甲基酶和先锋因子的染色质调控重要机制,该机制可控制ER功能。重要的是,我们通过全球基因表达分析表明,KDM3A / KDM4B / FOXA1共同调控的基因签名丰富了促增殖和ER靶基因集,这表明废除该网络可能是一种有效的治疗策略。最后,我们显示KDM3A和KDM4B的耗竭比每种单独的酶的敲除对ER活性和细胞生长具有更大的抑制作用,这表明靶向这两种酶代表了ER驱动的乳腺癌的潜在有效治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号